Today we feature the workshop Map the Strengths, Weaknesses, & Defenses of your IP Assets to Prepare for the Challenges of the Follow-On Process . This in-depth workshop will offer an interactive, case-study-driven examination of the latest advances in the patent exchange process for sponsors of follow-on biologics. These legal interactions have been thoroughly described in advance, but the pathway has some potential weaknesses concerning oversight and following up on lapses. How can biosimilar sponsors best firm up these methods? The Business of Biosimilars and Generic Drugs will take place September 10-12, 2012 in Boston, MA. For more information on the rest of the program, download the agenda. If you'd like to join us in Boston, register today and mention code XP1786BLOG to save 25% off the standard rate!
 |
| Speaker Michael Castagna |
Featured Presenters: Michael Castagna, Executive Director of Immunoscience, BRISTOL-MYERS SQUIBB
Mark Hyman, Assistant General Counsel, Litigation & IP, HUMAN GENOME SCIENCES
About the Workshop: Intended for IP and legal counsel marketing professionals with
an established background in either brands or biosimilars. The pathway for biosimilar approval in the U.S. depends on extremely detailed sharing of patent portfolios between biosimilar and originator companies – but so far lacks a rigid system of oversight or accountability. Instead of letting this uncertainty slow down your work, you need to learn to accommodate and work around it. This interactive and case-study-driven session will focus on preparations for the step-by-step patent analysis, challenge, and defense stage of an abbreviated biologics license application.
- • Pre-empt patent challenges by identifying your weakest links
- • Investigate and accelerate the creation of process and manufacturing patents
- • Differentiate your new follow-on product from competitors
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment